Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2013
10/17/2013WO2013154707A1 Co-polymer conjugates
10/17/2013WO2013154666A1 Hollow drug-filled stent and method of forming hollow drug-filled stent
10/17/2013WO2013154570A1 Synthetic mechanical hemostatic composition, method of making and use thereof
10/17/2013WO2013154513A1 The use of 5-ht7 receptor antagonists including some atypical antipsychotics as antipruritic agents
10/17/2013WO2013154512A1 Pharmaceutical formulations comprising dexibuprofen
10/17/2013WO2013154511A1 Film tablet formulations comprising dexibuprofen
10/17/2013WO2013154503A1 Methods for bladder cancer therapy using baculoviral vectors
10/17/2013WO2013154410A1 Use of phenobarbital (phb) in small doses in the treatment of autonomic dysregulations such as sympathetic hyperactivity
10/17/2013WO2013154409A1 Use of venlafaxine in the treatment of autonomic dysregulations with sympathetic deficit
10/17/2013WO2013154408A1 Use of maprotiline in the treatment of autonomic dysregulation with sympathetic deficiency
10/17/2013WO2013154373A1 Composition comprising purine derivatives or salt thereof for preventing or treating atopic dermatitis
10/17/2013WO2013154359A1 Nano-emulsion composition and method for producing the same
10/17/2013WO2013154347A1 Liquid formulation for oral administration comprising ambroxol, levodropropizine and buffering agent, and method for preparing the same
10/17/2013WO2013154335A1 Method for preparing furofuran lignan compound
10/17/2013WO2013154303A1 Pyrimidine derivative substituted with novel hydrazine, and use thereof
10/17/2013WO2013154209A1 Antiprotozoan composition containing caspofungin or its salt and biguanide compound or its salt
10/17/2013WO2013154192A1 Medicinal composition for treating infarction
10/17/2013WO2013154173A1 Amidopyridine derivative, and use thereof
10/17/2013WO2013154163A1 Novel 5-aryl-1,2-thiazinane derivative
10/17/2013WO2013154128A1 Novel arteriosclerosis treatment drug composition and method for screening arteriosclerosis treatment drugs
10/17/2013WO2013154109A1 Novel 1-substituted indazole derivative
10/17/2013WO2013154080A1 Aryloxyurea compound and pest control agent
10/17/2013WO2013154045A1 Composition for injectable solution
10/17/2013WO2013154016A1 Ophthalmic composition
10/17/2013WO2013153821A1 Pdk4 inhibitor and use thereof
10/17/2013WO2013153559A1 Fulvestrant formulations
10/17/2013WO2013153539A1 Tricyclic compounds as tec kinase inhibitors
10/17/2013WO2013153535A1 TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
10/17/2013WO2013153532A1 Phthalocyanine compounds useful as reca inhibitors and methods of using same
10/17/2013WO2013153496A1 Anesthetic neutralization methods
10/17/2013WO2013153394A1 Quinolonones with antibacterial properties
10/17/2013WO2013153357A1 Anti-malarial agents
10/17/2013WO2013153221A1 Vesicular formulations for use in the treatment of pain or reduced mobility of a joint
10/17/2013WO2013153162A1 Polymorph of rilpivirine hydrochloride
10/17/2013WO2013153146A1 Aggregate particles
10/17/2013WO2013153145A1 Oral film containing opiate enteric-release beads
10/17/2013WO2013153139A1 Methods for the treatment and diagnosis of acute leukemia
10/17/2013WO2013153129A1 Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
10/17/2013WO2013153111A1 Pharmaceutical composition containing an unsaturated fatty acid enriched with oxygen and an organic solvent
10/17/2013WO2013153082A1 Methods for the treatment of nonalcoholic steatohepatitis
10/17/2013WO2013153055A1 Process for the preparation of a viral protease inhibitor in amorphous form
10/17/2013WO2013152848A1 Glycomimetics as pseudomonas aeruginosa lectin inhibitors
10/17/2013WO2013152838A1 Preparation for topical application to mucosa containing polyhexanide as active ingredient
10/17/2013WO2013152717A1 Fused pyrimidine compound, and preparation method, intermediate, composition， and uses thereof
10/17/2013WO2013152712A1 3-cyanoanilinoalkylarylpiperazine derivative and use thereof in preparing drugs
10/17/2013WO2013152704A1 5-amino-1,4-dihydro-1,8-naphthyridine derivative and pharmaceutical composition and use thereof
10/17/2013WO2013152683A1 Bicycle substituted pyrazoloneazo derivatives and preparation method and use thereof
10/17/2013WO2013152654A1 Process for preparation of benzylbenzene sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
10/17/2013WO2013152641A1 Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
10/17/2013WO2013152590A1 Metal-polysaccharide conjugates: compositions,synthesis and methods for cancer therapy
10/17/2013WO2013152476A1 Process for the preparation of benzylbenzene sglt2 inhibitors
10/17/2013WO2013152470A1 Ethyl salicylate glycosides compound, synthetic method and application thereof
10/17/2013WO2013152441A1 Composition for prevention of vasoactivity in the treatment of blood loss and anemia
10/17/2013WO2013152392A1 Viral polymerase inhibitors
10/17/2013WO2013152391A1 Viral polymerase inhibitors
10/17/2013WO2013124874A3 Glucose derivatives bound to arsenic for use in the treatment of tumour
10/17/2013WO2013124748A4 Novel polymorphs of azilsartan medoxomil potassium
10/17/2013WO2013116821A9 Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer
10/17/2013WO2013069027A9 Processes for the preparation of cabazitaxel involving c(7) -oh and c(13) -oh silylation or just c(7) -oh silylation
10/17/2013WO2013042111A3 Platelet analysis system
10/17/2013WO2012136351A8 Tapentadol for treating pain associated with trigeminal neuralgia
10/17/2013WO2012116402A9 Binder powders
10/17/2013WO2012104007A3 7-azaindole derivatives
10/17/2013WO2012088525A3 Methods for treating copd
10/17/2013WO2012058091A3 Aripiprazole compositions and methods for its transdermal delivery
10/17/2013WO2012051559A3 Compositions and methods of treating pulmonary hypertension
10/17/2013WO2007083173A3 Mononucleotides and mononucleosides for use in therapy
10/17/2013US20130276158 Methods and compositions for rna interference
10/17/2013US20130274704 Augmented cognitive training
10/17/2013US20130274689 Method for Reducing or Preventing Transplant Rejection in the Eye and Intraocular Implants for Use Therefor
10/17/2013US20130274650 Stabilized ketorolac compositions
10/17/2013US20130274459 Methods for isolating crystalline form i of 5-azacytidine
10/17/2013US20130274346 Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (ndga)
10/17/2013US20130274343 Water Soluble Composition Comprising Curcumin Having Enhanced Bioavailability and Process Thereof
10/17/2013US20130274342 Compositions and methods for treating cough
10/17/2013US20130274341 Methods and Compositions for Treatment of Dermal Conditions
10/17/2013US20130274338 Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
10/17/2013US20130274337 Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
10/17/2013US20130274336 Trans10:cis12 isomer of conjugated linoleic acid as a therapeutic and preventative agent for hypertension specific to pregnancy
10/17/2013US20130274335 Pet Food Compositions and Methods for Treating Arthritis and Inflammation Associated with Arthritis
10/17/2013US20130274331 Method for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halofenic Acid and an Anti-Inflammatory Agent
10/17/2013US20130274330 Oral dosage form
10/17/2013US20130274328 Ferric citrate dosage forms
10/17/2013US20130274323 Method of inhibiting abcg2 and other treatment methods
10/17/2013US20130274321 Topical Compositions with Cannabis Extracts
10/17/2013US20130274319 Intraluminal device with a coating containing a therapeutic agent
10/17/2013US20130274309 Compositions and methods for non-parenteral delivery of oligonucleotides
10/17/2013US20130274308 Modulation of factor 11 expression
10/17/2013US20130274303 Methods and compositions for treatment of drug addiction
10/17/2013US20130274302 Topical localized isoxazoline formulation comprising glycofurol
10/17/2013US20130274301 Novel Use of Leflunomide and Malononitrilamides
10/17/2013US20130274300 Extended Release Tablet Formulation Containing Pramipexole or a Pharmaceutically Acceptable Salt Thereof
10/17/2013US20130274297 Pharmaceutical composites of poorly water soluble drugs and polymers
10/17/2013US20130274296 Remelted ingestible products
10/17/2013US20130274295 Pioglitazone for use in the treatment of adrenoleukodystrophy
10/17/2013US20130274294 4-(Hetero)Aryl-Ethynyl-Octahydro-Indole-1-Esters
10/17/2013US20130274293 Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity
10/17/2013US20130274290 Methods of use of cyclic amide derivatives to treat sigma receptor mediated disorders
10/17/2013US20130274286 NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY
10/17/2013US20130274282 Compositions and methods comprising celecoxib or related compounds and dextromethorphan
1 ... 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 ... 7860